| A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer. (NCT05335993) | CanariaBio Inc. | 2022-07-25 |
| Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers (NCT03564340) | Regeneron Pharmaceuticals | 2018-05-21 |
| Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer (NCT02785250) | ImmunoVaccine Technologies, Inc. (IMV Inc.) | 2016-04-01 |
| Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT02122185) | University of Chicago | 2015-02-25 |
| Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer (NCT02046421) | University of Chicago | 2013-11-01 |
| Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT01962948) | Fox Chase Cancer Center | 2013-10-09 |
| Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer (NCT01853644) | Northwestern University | 2013-06-06 |
| Auranofin in Treating Patients With Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (NCT01747798) | Mayo Clinic | 2012-11-02 |
| Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer (NCT01536054) | Roswell Park Cancer Institute | 2012-08-20 |
| Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer (NCT01652794) | Case Comprehensive Cancer Center | 2012-05-01 |
| Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast Cancer (NCT01764789) | Ohio State University Comprehensive Cancer Center | 2010-10-01 |
| SJG-136 in Treating Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer That Did Not Respond to Previous Treatment With Cisplatin or Carboplatin (NCT01200797) | National Cancer Institute (NCI) | 2010-07-01 |
| Sunitinib Malate in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer (NCT00388037) | National Cancer Institute (NCI) | 2007-01-01 |
| Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube Cancer (NCT00278343) | National Cancer Institute (NCI) | 2006-04-01 |
| Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT02050009) | Fox Chase Cancer Center | |